Author

Oliver Gorka

University of FreiburgORCID 0000-0002-8245-3008Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Olaf GroßiD· 3 shared Almut DufneriD· 1 shared Andreas VlachosiD· 1 shared Anna Kostina· 1 shared Ariane LehmanniD· 1 shared Asma Y. AlrawashdehiD· 1 shared Bénédikt JacobsiD· 1 shared Bertram BengschiD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMolecular Biology

Olaf GroßORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular BiologyLeukemiaPeer-reviewedAug 11, 2026

USP8 Controls Proteostasis Pathways in B Cells and Multiple Myeloma

Almut Dufner, Fabien Théry, Gianni Monaco…·Klaus‐Peter Knobeloch

This study investigates the role of USP8 in B-cell development and multiple myeloma, showing its impact on proteostasis and identifying potential therapeutic strategies.

1 citation

mouseproteomics

𝕏 PostBluesky

ImmunologyJournal of Molecular BiologyPeer-reviewedJul 1, 2026

NEK7 accelerates NLRP3 inflammasome activation

Svenja Wöhrle, Tamara Ćiković, Clara Dufossez…·Olaf Groß

This study shows NEK7 accelerates NLRP3 inflammasome activation but is not essential, suggesting potential limitations in targeting this interaction for drug development.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologySignal Transduction and Targeted TherapyPeer-reviewedJan 16, 2026

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Philipp Hafner, Steffen Johannes Keller, Xun Chen…·Dietrich Alexander Ruess

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.

9 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky